Navigation Links
Array BioPharma To Present At The Wells Fargo Securities Research And Economics 2013 Healthcare Conference
Date:6/13/2013

BOULDER, Colo., June 13, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities Research and Economics 2013 Healthcare Conference in Boston.  The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Event:Wells Fargo Securities Research and Economics 2013 Healthcare ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Wednesday, June 19, 2013Time:9:15 a.m. Eastern Time Location:InterContinental Hotel,  Boston, MAWebcast:www.arraybiopharma.comAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis expects to begin Phase 3 trials evaluating Array-invented MEK162 in NRAS-mutant melanoma and in BRAF-mutant melanoma in 2013.  In addition, Array will begin a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the license agreement with Novartis in 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Array BioPharma Announces Exercise Of Underwriters Option To Purchase An Additional $17.25 Million Of 3.00% Convertible Senior Notes
2. New Date And Time For Array BioPharma Presentation At The Jefferies 2013 Global Healthcare Conference
3. Array BioPharma Announces Proposed Public Offering of Convertible Debt
4. Two Array Invented MEK Inhibitors Showcased At ASCO
5. Array BioPharma To Present At The Jefferies 2013 Global Healthcare Conference
6. Oncothyreon and Array Announce Collaboration to Develop and Commercialize anti-HER2 Compound ARRY-380
7. Array BioPharma Announces Clinical Data Presentations At The 2013 ASCO Annual Meeting
8. Array Announces Global Phase 3 Trial Evaluating MEK162 In Patients With Low-Grade Serous Ovarian Cancer
9. Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
10. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
11. Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017 Caris Life Sciences, a leading ... promise of precision medicine, today announced results from ... its molecular profiling approach in guiding therapeutic strategies ... plus (CGP+) with Caris Molecular Intelligence ® ... molecular level, leading to more therapeutic options and ...
(Date:9/7/2017)... BOTHELL, Wash. , Sept. 7, 2017   BioLife ... developer, manufacturer and marketer of proprietary clinical grade cell and ... media ("BioLife"), announces that Mike Rice , President and ... Rodman & Renshaw 19 th ... 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference ...
(Date:9/6/2017)... 2017   PDI , a leader in infection ... an educational session focused on the role of chlorhexidine ... at the 2017 Annual Scientific Meeting of the Association ... at the Phoenix Convention Center ... 16-19, will also feature PDI,s Prevantics® Device Swab ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... September 22, 2017 , ... ... fallacy of an obligatory tithe, and the freedom experienced when breaking free from ... of published author, Lysa M. Harrison. , Published by Christian Faith Publishing, Lysa ...
(Date:9/22/2017)... ... 22, 2017 , ... First Choice Emergency Room , ... year anniversary of its Houston-Fallbrook facility. , “We are honored to celebrate ... of First Choice Emergency Room Houston-Fallbrook. “It has been a pleasure serving the ...
(Date:9/22/2017)... CA (PRWEB) , ... September 22, 2017 , ... ... to help you brush more effectively even on the go. Their electric toothbrushes ... gingivitis and gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Letters From Home”: a moving compilation ... have value to God. “Letters From Home” is the creation of published author, John ... President’s Cabinet of Jerry Savelle Ministries International, who has traveled and ministered on four ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg freezing and embryo freezing ... have a slight statistical advantage for live births, frozen eggs offer many advantages, ... women undergoing medical treatment or who are concerned about the decline of their ...
Breaking Medicine News(10 mins):